Standard BioTools Q3 2024 GAAP EPS $(0.07) Beats $(0.09) Estimate, Sales $44.969M Beat $40.998M Estimate
Portfolio Pulse from Benzinga Newsdesk
Standard BioTools reported better-than-expected Q3 2024 results with a GAAP EPS of $(0.07), beating the estimate of $(0.09), and sales of $44.969M, surpassing the $40.998M estimate. Sales increased by 77.27% compared to the same period last year.

October 30, 2024 | 8:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Standard BioTools reported a Q3 2024 GAAP EPS of $(0.07), beating the $(0.09) estimate, and sales of $44.969M, exceeding the $40.998M estimate. Sales grew by 77.27% YoY.
The company's better-than-expected earnings and significant year-over-year sales growth are likely to positively impact its stock price in the short term. Beating both EPS and sales estimates indicates strong performance, which is typically viewed favorably by investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100